Added to YB: 2026-04-23
Pitch date: 2026-04-21
BANB.SW [bullish]
Bachem Holding AG
-1.79%
current return
Author Info
Value and Opportunity focuses on slow investing, special situations & the occasional wild punts Sign up for their newsletter.
Company Info
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.
Market Cap
CHF 5.2B
Pitch Price
CHF 69.90
Price Target
128.00 (+86%)
Dividend
1.30%
EV/EBITDA
24.80
P/E
34.94
EV/Sales
7.52
Sector
Life Sciences Tools and Services
Category
growth
Bachem AG: Riding the 'Golden Age of Peptides' with this Hidden Champion from Switzerland
BANB.SW (new position): Swiss polypeptide API leader riding 15% CAGR peptide market growth ('Golden Age') driven by Wegovy/Ozempic demand, pill adoption (70x molecule boost vs injection), triple agonist pipeline (Retatrutide '27), & oligonucleotide expansion. Western 'moat' from complex 180hr batch process + BIOSECURE Act blocking China. Family-owned (58%), expanding capacity via prepayments, minimal energy exposure. 3% position. Target CHF128/share + CHF6 div in 4yrs = 100% return (17% IRR) at 25x trailing P/E vs 27x '26. Risks: scale-up, insourcing, Semaglutide side effects, overcapacity.
Read full article (21 min)